Eun-Jung Rhee1, Se Eun Park1, Hyung Geun Oh2, Cheol-Young Park1, Ki-Won Oh1, Sung-Woo Park1, Ron Blankstein3, Jorge Plutzky4, Won-Young Lee5. 1. Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 2. Department of Neurology, Soonchunhyang University College of Medicine, Cheonan, Republic of Korea. 3. Non-Invasive Cardiovascular Imaging Program, Departments of Medicine and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 4. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Cambridge, MA, USA. 5. Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: drlwy@hanmail.net.
Abstract
OBJECTIVE: To investigate the statin eligibility and the predictabilities for cardiovascular disease between AHA/ACC and ATPIII guidelines, comparing those results to concomitant coronary artery calcium scores (CACS) in a large cohort of Korean individuals who met statin-eligibility criteria. METHODS: Among 19,920 participants in a health screening program, eligibility for statin treatment was assessed by the two guidelines. The presence and extent of coronary artery calcification (CAC) was measured by multi-detector computed tomography and compared among the various groups defined by the two guidelines. RESULTS: Applying the new ACC/AHA guideline to the health screening cohort increased the statin-eligible population from 18.7% (as defined by ATP III) to 21.7%. Statin-eligible subjects as defined only by ACC/AHA guideline manifested a higher proportion of subjects with CAC compared with those meeting only ATP-III criteria even after adjustment for age and sex (47.1 vs. 33.8%, p<0.01). Statin-eligible subjects as defined by ACC/AHA guideline showed higher odds ratio for the presence of CACS>0 compared with those meeting ATP-III criteria {3.493 (3.245∼3.759) vs. 2.865 (2.653∼3.094)}, which was attenuated after adjusted for age and sex. CONCLUSIONS: In this large Korean cohort, more subjects would have qualified for statin initiation under the new ACC/AHA guideline as compared with the proportion recommended for statin treatment by ATP III guideline. Among statin-eligible Korean health screening subjects, the new ACC/AHA guideline identified a greater extent of atherosclerosis as assessed by CACS as compared to ATP III guideline assessment.
OBJECTIVE: To investigate the statin eligibility and the predictabilities for cardiovascular disease between AHA/ACC and ATPIII guidelines, comparing those results to concomitant coronary artery calcium scores (CACS) in a large cohort of Korean individuals who met statin-eligibility criteria. METHODS: Among 19,920 participants in a health screening program, eligibility for statin treatment was assessed by the two guidelines. The presence and extent of coronary artery calcification (CAC) was measured by multi-detector computed tomography and compared among the various groups defined by the two guidelines. RESULTS: Applying the new ACC/AHA guideline to the health screening cohort increased the statin-eligible population from 18.7% (as defined by ATP III) to 21.7%. Statin-eligible subjects as defined only by ACC/AHA guideline manifested a higher proportion of subjects with CAC compared with those meeting only ATP-III criteria even after adjustment for age and sex (47.1 vs. 33.8%, p<0.01). Statin-eligible subjects as defined by ACC/AHA guideline showed higher odds ratio for the presence of CACS>0 compared with those meeting ATP-III criteria {3.493 (3.245∼3.759) vs. 2.865 (2.653∼3.094)}, which was attenuated after adjusted for age and sex. CONCLUSIONS: In this large Korean cohort, more subjects would have qualified for statin initiation under the new ACC/AHA guideline as compared with the proportion recommended for statin treatment by ATP III guideline. Among statin-eligible Korean health screening subjects, the new ACC/AHA guideline identified a greater extent of atherosclerosis as assessed by CACS as compared to ATP III guideline assessment.
Authors: Yashashwi Pokharel; Lynne Steinberg; Winston Chan; Julia M Akeroyd; Peter H Jones; Vijay Nambi; Khurram Nasir; Laura Petersen; Christie M Ballantyne; Salim S Virani Journal: Atherosclerosis Date: 2016-01-06 Impact factor: 5.162
Authors: Byung Sub Moon; Jongho Kim; Ji Hyun Kim; Young Youl Hyun; Se Eun Park; Hyung Geun Oh; Cheol Young Park; Won Young Lee; Ki Won Oh; Kyu Beck Lee; Hyang Kim; Sung Woo Park; Eun Jung Rhee Journal: Endocrinol Metab (Seoul) Date: 2016-08-26
Authors: Mohamad I Jarrah; Muhannad J Ababneh; Loai Issa Tawalbeh; Ayman J Hammoudeh; Hanan M Barukba; Ahmad Othman Journal: Ann Med Surg (Lond) Date: 2020-12-29